Anticoagulation in the acute and long-term management of Kawasaki disease

Progress in Pediatric Cardiology

Volumn 19, Issue 2 SPEC.ISS., 2004, Pages 179-188

  Williams, Richard V ^a   Tcheng, Wendy Y ^a   Minich, L Luann ^a  

^a PNM   (United States)

Author keywords

Anticoagulation therapy; Antiplatelet agents; Kawasaki disease; Thrombolytic agents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ACUTE DISEASE; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CHILD; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; CORONARY ARTERY THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HUMAN; LONG TERM CARE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING;

EID: 8444249209     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2004.08.012     Document Type: Article

References (96)

1. J.W. Newburger, M. Takahashi, A.S. Beiser, J.C. Burns, J. Bastian, and K.J. Chung A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome N. Engl. J. Med. 324 23 1991 1633 1639
2. A. Suzuki, M. Yamagishi, K. Kimura, H. Sugiyama, Y. Arakaki, and T. Kamiya Functional behavior and morphology of the coronary artery wall in patients with Kawasaki disease assessed by intravascular ultrasound J. Am. Coll. Cardiol. 27 2 1996 291 296
3. R. Yamakawa, M. Ishii, T. Sugimura, T. Akagi, G. Eto, and M. Iemura Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine J. Am. Coll. Cardiol. 31 5 1998 1074 1080
4. R. Dhillon, P. Clarkson, A.E. Donald, A.J. Powe, M. Nash, and V. Novelli Endothelial dysfunction late after Kawasaki disease Circulation 94 9 1996 2103 2106
5. R.F. Furchgott, and J.V. Zawadzki The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature 288 5789 1980 373 376
6. S. Moncada, M.W. Radomski, and R.M. Palmer Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function Biochem. Pharmacol. 37 13 1988 2495 2501
7. S. Moncada, and J.R. Vane Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls N. Engl. J. Med. 300 20 1979 1142 1147
8. K. Nakatani, S. Takeshita, H. Tsujimoto, Y. Kawamura, T. Tokutomi, and I. Sekine Circulating endothelial cells in Kawasaki disease Clin. Exp. Immunol. 131 3 2003 536 540
9. D.R. Fulton, C. Meissner, and M.B. Peterson Effects of current therapy of Kawasaki disease on eicosanoid metabolism Am. J. Cardiol. 61 15 1988 1323 1327
10. M. Fujieda, N. Oishi, and T. Kurashige Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment Clin. Exp. Immunol. 107 1 1997 120 126
11. K. Tsuruta, T. Saji, T. Umezawa, N. Matsuo, and M. Ishizaki Urinary excretion of prostacyclin in Kawasaki Disease before and after gammaglobulin H. Kato Kawasaki Disease 1995 Elsevier Amsterdam 257 260
12. Y. Mitani, Y. Okuda, H. Shimpo, F. Uchida, K. Hamanaka, and K. Aoki Impaired endothelial function in epicardial coronary arteries after Kawasaki disease Circulation 96 2 1997 454 461
13. A.S. Dajani, K.A. Taubert, M.A. Gerber, S.T. Shulman, P. Ferrieri, and M. Freed Diagnosis and therapy of Kawasaki disease in children Circulation 87 5 1993 1776 1780
14. T. Yokoyama, H. Kato, and E. Ichinose Aspirin treatment and platelet function in Kawasaki disease Kurume Med. J. 27 1 1980 57 61
15. K. Niwa, H. Aotsuka, H. Hamada, M. Uchishiba, M. Terai, and H. Niimi Thrombocytopenia: a risk factor for acute myocardial infarction during the acute phase of Kawasaki disease Coron. Artery Dis. 6 11 1995 857 864
16. A.S. Beiser, M. Takahashi, A.L. Baker, R.P. Sundel, and J.W. Newburger A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group Am. J. Cardiol. 81 9 1998 1116 1120
17. K. Yamada, T. Fukumoto, A. Shinkai, A. Shirahata, and T. Meguro The platelet functions in acute febrile mucocutaneous lymph node syndrome and a trial of prevention for thrombosis by antiplatelet agent Nippon Ketsueki Gakkai Zasshi 41 4 1978 791 802
18. K. Yamada, A. Shirahata, and M. Inagaki Coagulation abnormalities in Kawasaki disease Prog. Clin. Biol. Res. 250 1987 239 250
19. J.C. Burns, M.P. Glode, S.H. Clarke, J. Wiggins Jr., and W.E. Hathaway Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms J. Pediatr. 105 2 1984 206 211
20. M.P. Glode, L.S. Joffe, J. Wiggins Jr., S.H. Clarke, and W.E. Hathaway Effect of intravenous immune globulin on the coagulopathy of Kawasaki syndrome J. Pediatr. 115 3 1989 469 473
21. T. Hidaka, M. Nakano, T. Ueta, Y. Komatsu, and M. Yamamoto Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease J. Pediatr. 102 1 1983 94 96
22. D. Collen, and H.R. Lijnen Basic and clinical aspects of fibrinolysis and thrombolysis Blood 78 12 1991 3114 3124
23. M. Andrew, P. Vegh, M. Johnston, J. Bowker, F. Ofosu, and L. Mitchell Maturation of the hemostatic system during childhood Blood 80 8 1992 1998 2005
24. H. Senzaki, T. Kobayashi, H. Nagasaka, H. Nakano, S. Kyo, and Y. Yokote Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy Pediatr. Res. 53 6 2003 983 988
25. M. Sakai, K. Asayama, T. Otabe, T. Kohri, and A. Shirahata Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease Clin. Appl. Thromb. Hemost. 7 3 2001 214 218
26. I. Juhan-Vague, S.D. Pyke, M.C. Alessi, J. Jespersen, F. Haverkate, and S.G. Thompson Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities Circulation 94 9 1996 2057 2063
27. M. Albisetti, A.K. Chan, B.W. McCrindle, D. Wong, P. Vegh, and M. Adams Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease Blood Coagul. Fibrinolysis 14 2 2003 181 186
28. Y. Kuramochi, T. Ohkubo, N. Takechi, D. Fukumi, Y. Uchikoba, and S. Ogawa Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease Pediatr. Int. 42 5 2000 470 475
29. K. Hamaoka, Z. Onouchi, Y. Kamiya, and K. Sakata Evaluation of coronary flow velocity dynamics and flow reserve in patients with Kawasaki disease by means of a Doppler guide wire J. Am. Coll. Cardiol. 31 4 1998 833 840
30. A. Suzuki, S. Miyagawa-Tomita, K. Komatsu, T. Nishikawa, Y. Sakomura, and T. Horie Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study Circulation 101 25 2000 2935 2941
31. T. Sugimura, H. Kato, O. Inoue, T. Fukuda, N. Sato, and M. Ishii Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease Circulation 89 1 1994 258 265
32. Z. Onouchi, K. Hamaoka, Y. Kamiya, S. Hayashi, Y. Ohmochi, and K. Sakata Transformation of coronary artery aneurysm to obstructive lesion and the role of collateral vessels in myocardial perfusion in patients with Kawasaki disease J. Am. Coll. Cardiol. 21 1 1993 158 162
33. K. Tatara, and S. Kusakawa Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study J. Pediatr. 111 5 1987 705 710
34. M.H. Kroll, J.D. Hellums, L.V. McIntire, A.I. Schafer, and J.L. Moake Platelets and shear stress Blood 88 5 1996 1525 1541
35. C.P. Ratnatunga, S.F. Edmondson, G.M. Rees, and I.B. Kovacs High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation Circulation 85 3 1992 1077 1082
36. A.I. Schafer Antiplatelet therapy Am. J. Med. 101 2 1996 199 209
37. L.A. Garcia Rodriguez The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data Clin. Exp. Rheumatol. 19 6 Suppl. 25 2001 S41 S44
38. P.A. Gum, K. Kottke-Marchant, E.D. Poggio, H. Gurm, P.A. Welsh, and L. Brooks Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am. J. Cardiol. 88 3 2001 230 235
39. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J. Clin. Invest. 69 6 1982 1366 1372
40. F. Ichida, N.S. Fatica, M.A. Engle, J.E. O'Loughlin, A.A. Klein, and M.S. Snyder Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin Pediatrics 80 6 1987 828 835
41. K. Durongpisitkul, V.J. Gururaj, J.M. Park, and C.F. Martin The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment Pediatrics 96 6 1995 1057 1061
42. M. Terai, and S.T. Shulman Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose J. Pediatr. 131 6 1997 888 893
43. A.M. McMorrow Tuohy, L.Y. Tani, F. Cetta, M.B. Lewin, B.W. Eidem, and P. Van Buren How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am. J. Cardiol. 88 3 2001 328 330
44. A.S. Dajani, K.A. Taubert, M. Takahashi, F.Z. Bierman, M.D. Freed, and P. Ferrieri Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association Circulation 89 2 1994 916 922
45. M. Andrew, L. Mitchell, P. Vegh, and F. Ofosu Thrombin regulation in children differs from adults in the absence and presence of heparin Thromb. Haemost. 72 6 1994 836 842
46. P. Monagle, A.D. Michelson, E. Bovill, and M. Andrew Antithrombotic therapy in children Chest 119 1 Suppl. 2001 344S 370S
47. J.H. Lee, H.Y. Hung, and F.Y. Huang Kawasaki disease with Reye syndrome: report of one case Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 33 1 1992 67 71
48. M. Takahashi, and W. Mason Kawasaki syndrome, Reye syndrome, and aspirin Pediatrics 77 4 1986 616 617
49. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, and B. Tournier Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N. Engl. J. Med. 345 25 2001 1809 1817
50. H. Kato, E. Ichinose, and T. Kawasaki Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases J. Pediatr. 108 6 1986 923 927
51. E. Seifried, and P. Tanswell Current developments in thrombolytic therapy using novel plasminogen activators Arzneimittelforschung 39 11 1989 1474 1482
52. P. Tanswell, U. Tebbe, K.L. Neuhaus, L. Glasle-Schwarz, J. Wojcik, and E. Seifried Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction J. Am. Coll. Cardiol. 19 5 1992 1071 1075
53. D.M. Burtt, P. Pollack, and J.A. Bianco Intravenous streptokinase in an infant with Kawasaki's disease complicated by acute myocardial infarction Pediatr. Cardiol. 6 6 1986 307 311
54. C.D. Liang, S.C. Huang, W.J. Su, H.Y. Chen, and C.H. Lee Successful intravenous streptokinase treatment of a child with Kawasaki disease complicated by acute myocardial infarction Catheter. Cardiovasc. Diagn. 35 2 1995 139 145
55. H. Kato, O. Inoue, E. Ichinose, T. Akagi, and N. Sato Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction Acta Paediatr. Jpn. 33 1 1991 27 35
56. A. Suzuki, K. Tetsuro, Y. Ono, and M. Kinoshita Thrombolysis in the treatment of patients with Kawasaki disease Cardiol. Young 3 1993 207 215
57. F. Katayama, S. Hiraishi, N. Takeda, and H. Misawa Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction Heart 78 6 1997 621 622
58. H. Horigome, T. Sekijima, and T. Miyamoto Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease Heart 78 5 1997 517 518
59. M. Nakagawa, N. Watanabe, M. Okuno, N. Okamoto, and H. Fujino Effects of intracoronary tissue-type plasminogen activator treatment in Kawasaki disease and acute myocardial infarction Cardiology 94 1 2000 52 57
60. S. Tsubata, F. Ichida, Y. Hamamichi, A. Miyazaki, I. Hashimoto, and T. Okada Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease Pediatr. Cardiol. 16 4 1995 186 189
61. A.A. Gupta, M. Leaker, M. Andrew, P. Massicotte, L. Liu, and L.N. Benson Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children J. Pediatr. 139 5 2001 682 688
62. M.A. Mascelli, E.T. Lance, L. Damaraju, C.L. Wagner, H.F. Weisman, and R.E. Jordan Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade Circulation 97 17 1998 1680 1688
63. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators N. Engl. J. Med. 336 24 1997 1689 1696
64. G.W. Stone, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tcheng, and J.J. Griffin Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction N. Engl. J. Med. 346 13 2002 957 966
65. S.H. Tam, P.M. Sassoli, R.E. Jordan, and M.T. Nakada Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins Circulation 98 11 1998 1085 1091
66. C.H. Wu, Y.C. Chen, G. Hsiao, C.H. Lin, C.M. Liu, and J.R. Sheu Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty Thromb. Res. 101 3 2001 127 138
67. A.M. Lincoff, D.J. Kereiakes, M.A. Mascelli, L.I. Deckelbaum, E.S. Barnathan, and K.K. Patel Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization Circulation 104 2 2001 163 167
68. R.H. Chandwaney, T. Stathopoulos, J. Sunew, D. McPherson, and C.J. Davidson Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki's disease J. Invasive Cardiol. 13 9 2001 651 653
69. S.P. Etheridge, L.Y. Tani, L.L. Minich, and J.R. Revenaugh Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease Catheter. Cardiovasc. Diagn. 45 3 1998 264 268
70. R.V. Williams, V.M. Wilke, L.Y. Tani, and L.L. Minich Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109 1 2002 E4
71. G.C. Mok, R.Y. Sung, M.C. Yam, A.A. Arifi, W.W. Lam, and T.F. Fok A child with Kawasaki disease who survived after rupture of a coronary artery aneurysm Eur. J. Pediatr. 162 9 2003 634 636
72. D.R. Fulton, and J.W. Newburger Long-term cardiac sequelae of Kawasaki disease Curr. Rheumatol. Rep. 2 4 2000 324 329
73. J.W. Newburger Kawasaki disease Curr. Treatm. Opt. Cardiovasc. Med. 2 3 2000 227 236
74. M. Takahashi Management of giant coronary artery aneurysms due to Kawasaki syndrome ACC Curr. J. Rev. 1996 (July/August) 1996 74 76
75. A.G. Turpie, M. Gent, A. Laupacis, Y. Latour, J. Gunstein, and F. Basile A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement N. Engl. J. Med. 329 8 1993 524 529
76. R.E. Jordan, G.M. Oosta, W.T. Gardner, and R.D. Rosenberg The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin J. Biol. Chem. 255 21 1980 10081 10090
77. M. Albisetti, and M. Andrew Low molecular weight heparin in children Eur. J. Pediatr. 161 2 2002 71 77
78. P. Massicotte, M. Adams, V. Marzinotto, L.A. Brooker, and M. Andrew Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study J. Pediatr. 128 3 1996 313 318
79. D. Dix, M. Andrew, V. Marzinotto, K. Charpentier, S. Bridge, and P. Monagle The use of low molecular weight heparin in pediatric patients: a prospective cohort study J. Pediatr. 136 2000 439 445
80. M. Fujita, S. Sasayama, H. Asanoi, H. Nakajima, O. Sakai, and A. Ohno Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina Circulation 77 5 1988 1022 1029
81. A.A. Quyyumi, J.G. Diodati, E. Lakatos, R.O. Bonow, and S.E. Epstein Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study J. Am. Coll. Cardiol. 22 3 1993 635 641
82. S. Tateno, M. Terai, K. Niwa, T. Jibiki, H. Hamada, and K. Yasukawa Alleviation of myocardial ischemia after Kawasaki disease by heparin and exercise therapy Circulation 103 21 2001 2591 2597
83. T. Kobayashi, and K. Sone Effect of dipyridamole on the blood flow in coronary aneurysms resulting from Kawasaki disease Pediatr. Cardiol. 15 6 1994 263 267
84. J.M. Boeynaems, A. Van Coevorden, and D. Demolle Dipyridamole and vascular prostacyclin production Biochem. Pharmacol. 35 17 1986 2897 2902
85. S. Moncada, and R. Korbut Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin Lancet 1 8077 1978 1286 1289
86. G.A. FitzGerald Dipyridamole N. Engl. J. Med. 316 20 1987 1247 1257
87. S. Yamamoto, H. Matsuura, T. Umezawa, T. Saji, N. Matsuo, and Y. Yabe Dipyridamole-induced ischemia in a child with jeopardized collaterals after Kawasaki syndrome Jpn. Heart J. 31 6 1990 867 874
88. R.J. Gryglewski, R. Korbut, J. Swies, E. Kostka Trabka, K. Bieron, and J. Robak Thrombolytic action of ticlopidine: possible mechanisms Eur. J. Pharmacol. 308 1 1996 61 67
89. F. Balsano, P. Rizzon, F. Violi, D. Scrutinio, C. Cimminiello, and F. Aguglia Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group Circulation 82 1 1990 17 26
90. M.B. Leon, D.S. Baim, J.J. Popma, P.C. Gordon, D.E. Cutlip, and K.K. Ho A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N. Engl. J. Med. 339 23 1998 1665 1671
91. M. O'Brien, I.A. Parness, E.J. Neufeld, A.L. Baker, R.P. Sundel, and J.W. Newburger Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease Pediatrics 105 5 2000 E64
92. M. Gent, J.A. Blakely, J.D. Easton, D.J. Ellis, V.C. Hachinski, and J.W. Harbison The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1 8649 1989 1215 1220
93. P. Savi, M.C. Laplace, J.P. Maffrand, and J.M. Herbert Binding of [3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine J. Pharmacol. Exp. Ther. 269 2 1994 772 777
94. M. Humbert, P. Nurden, C. Bihour, J.M. Pasquet, J. Winckler, and E. Heilmann Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation Arterioscler. Thromb. Vasc. Biol. 16 12 1996 1532 1543
95. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet 348 9038 1996 1329 1339
96. R.J. Peters, S.R. Mehta, K.A. Fox, F. Zhao, B.S. Lewis, and S.L. Kopecky Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 14 2003 1682 1687